Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

Explore

The Xanamem® Pipeline

Alzheimer’s
Disease

Major Depressive
Disorder

Fragile X
Syndrome

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Cognitive impairment in early

Alzheimer’s Disease

Find out more

Biomarker analysis in patients with mild AD

Cognitive benefit in patients with early stages of AD

Pivotal trials focused on cognitive enhancement

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Depression

with cognitive impairment

Find out more

Depression and cognitive impairment

Pivotal trials assessing both depression and cognitive impairment

Diseases to be studied

Phase 2 placebo-controlled trials

Outlook

Anxiety, sleep &
behavioral problems in

Fragile X Syndrome

Find out more

Proof of concept in adolescent and young adult males

Pending alternative funding e.g. partnerships or grants

The Actinogen phase 2 depression trial has closed recruitment

The Actinogen phase 2 Alzheimer’s disease trial is now recruiting

Find Out More

Stay updated

If you would like to receive our latest news and updates, you can join our email distribution list. Simply register your details.



    Back
    to top